A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Trial Profile

A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Adenocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 13 Nov 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Dec 2015.
    • 07 Apr 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top